Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

U.S. ready to help China on COVID-19 surge if Beijing asks - White House

Published 12/14/2022, 04:40 PM
Updated 12/14/2022, 04:47 PM
© Reuters. FILE PHOTO: Pandemic prevention workers in protective suits cross a street as coronavirus disease (COVID-19) outbreaks continue in Beijing, December 9, 2022. REUTERS/Thomas Peter

WASHINGTON (Reuters) - The United States is prepared to help China deal with a surge of COVID-19 infections if Beijing requests assistance, the White House said on Wednesday.

John Kirby (NYSE:KEX), the White House national security spokesperson, told reporters that China has not requested help at this stage.

"We have made that point that we are prepared to help in any way they might find acceptable. That was true back when the pandemic was raging, and that is true today," Kirby told reporters.

White House national security adviser Jake Sullivan told reporters earlier this week that U.S. and Chinese officials had discussed COVID-19 and countries' different response to the pandemic were discussed at U.S.-Chinese meetings, but gave no details.

"I want to give an opportunity for us to be able to have those conversations in sensitive diplomatic channels. And we’ll see what, if anything, comes out of it," he said.

China Meheco Group Co Ltd said on Wednesday it signed an agreement with U.S. drugmaker Pfizer Inc (NYSE:PFE) to import and distribute its oral COVID-19 treatment Paxlovid in mainland China, as the country braces for a surge in patients after scaling back its "zero COVID" policy.

Pfizer already signed a deal in August for Chinese drugmaker Zhejiang Huahai <600521.SS. to produce Paxlovid in mainland China solely for patients there.

China began shifting away from the "zero COVID" policy just this month, after protests against the economically-damaging curbs that had been championed by President Xi Jinping. The change has spurred concerns about a surge in COVID cases.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.